32, 33 found significantly increased 3-nitrotyrosine (3-NT), a marker of oxidative protein damage, while noting a trend of increased 8-oxo-deoxyguanosine (8-oxo-dG), a marker of oxidative DNA damage
Pregnancy and lactation : The safety of DSIP use during pregnancy or lactation has not been established, and it is generally recommended that pregnant or breastfeeding individuals avoid its use
However, the vast array of options, each with varying efficacy, can overwhelm patients and physicians
However, we re-iterate that the side effects reported have been observed mostly when unregulated clinics provide the treatment in certain countries
Regulatory Status and Safety Concerns BPC-157 is not approved for clinical use by any major health authority worldwide: U.S